Guido J. K. Tricot

High Impact

Professor

UAMS primary UA Little Rock University of Arkansas

Also affiliated: Leiden University (1981); University of Iowa (2012–2023); University of Maryland, Baltimore (1999–2004); BC Cancer Agency (2013); Arkansas Children's Hospital (1998); University of Minnesota (1985); Hackensack University Medical Center (2003); NewYork–Presbyterian Hospital (2009); Central South University (2023); Radboud University Nijmegen (1984); Emory University (1993); Inserm (1981); Oregon Health & Science University (2007); University of Basel (2005); Medical College of Wisconsin (2003–2018); Cornell University (2009); University of Utah (2008–2019); Rega Institute for Medical Research (1983–1986); Indiana University Hospital (1989–1990); University of Perugia (1983); University of Arkansas Medical Center (1996–2023); Leiden University Medical Center (1981–1982); Universitair Ziekenhuis Leuven (1984–1987); Huntsman Cancer Institute (2009–2019); University of Iowa Hospitals and Clinics (2013–2019); Statistics Belgium (1981); Saint Vincent Health System (2003); University Medical Center (1992); Moffitt Cancer Center (2000); Institut National de Recherche en Santé Publique (2003); Fred Hutch Cancer Center (1997–2013); Acentech (United States) (1998); Central Arkansas Veterans Healthcare System (2001–2002); Cancer Research And Biostatistics (2003–2015); Carver Bible College (2015); Indiana Cancer Consortium (1988); Dana-Farber Cancer Institute (2003); Indiana University Bloomington (1989–1994); Myeloma UK (2007–2009); Walther Cancer Foundation (1990); University of Applied Management Studies (2024); Cancer Research Center (1990–2002); Winthrop Rockefeller Foundation (2020–2025); Frederick National Laboratory for Cancer Research (1997); Hôtel-Dieu de Paris (1980); Christ Hospital (1993); University of Minnesota Medical Center (1985); Urology of Indiana (1986); System Biosciences (United States) (1995); National Cancer Institute (1997–2013); Hôpital Saint-Louis (1981–2015); Millennium Engineering and Integration (United States) (2005); Center for Cancer Research (1997); John L. McClellan Memorial Veterans Hospital (1994); Avalon Pharma (United States) (2007); Third Xiangya Hospital (2023); Iowa City Public Library (2016); International Myeloma Foundation (2015); Arkansas Department of Agriculture (2000–2002); SWOG Cancer Research Network (2000); U-M Rogel Cancer Center (1999–2004); University of Iowa Holden Comprehensive Cancer Center (2015); Indiana University School of Medicine (1987–1993); Bristol-Myers Squibb (Switzerland) (2001); University of Oklahoma Health Sciences Center (2005); The Ohio State University (2007); Indiana University – Purdue University Indianapolis (1986–1996); Indiana University (1989–1993); University of Baltimore (2000); Science Applications International Corporation (United States) (1997); University of Bologna (2006); UCLouvain (1984); Stanford University (2007); KU Leuven (1982–2015)

Internal Med, College of Medicine

96 h-index 712 pubs 36,453 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Guido J. K. Tricot's research focuses on multiple myeloma, a hematologic malignancy. His work has investigated various aspects of the disease, including its molecular classification, gene expression profiling, and risk stratification. He has also explored therapeutic strategies such as hematopoietic stem cell transplantation and the use of agents like thalidomide and bortezomib.

Tricot has contributed to the development of response criteria for multiple myeloma and has examined the graft-versus-myeloma effect. His research has been published in numerous peer-reviewed journals, and he holds an h-index of 96 with over 36,000 citations from more than 700 publications. He maintains an active research group and collaborates with colleagues at the University of Arkansas for Medical Sciences, including Fenghuang Zhan and John D. Shaughnessy.

His scholarly contributions have led to his designation as a highly cited researcher. Tricot's work has been instrumental in advancing the understanding and treatment of multiple myeloma.

Metrics

h-index: 96
Publications: 712
Citations: 36,453

Positions

Professor publications 1994–2025

University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory

Selected Publications

Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

2 citations DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

1 citation DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

1 citation DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

Blood Cancer Journal 38 citations DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

8 citations DOI OpenAlex
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)

2 citations DOI OpenAlex
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)

4 citations DOI OpenAlex
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)

7 citations DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

Nature Communications 47 citations DOI OpenAlex
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)

8 citations DOI OpenAlex
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)

17 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

Gene expression profiling vs MRD assessment in Myeloma NIH Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator